ArticleOncotarget2017
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of
Abstract read
In one paragraph
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Trial
- Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies.International journal of molecular sciences · 2026Review
- Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B-cell-related epigenetic imprinting and genetic alterations.HemaSphere · 2026Article
- Chromoanagenesis Detection in Chronic Lymphocytic Leukemia.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Article
- Optical Genome Mapping as an Alternative to FISH-Based Cytogenetic Assessment in Chronic Lymphocytic Leukemia.Cancers · 2023Article
- Article
- Optical Genome Mapping: A Promising New Tool to Assess Genomic Complexity in Chronic Lymphocytic Leukemia (CLL).Cancers · 2022Article
- Review
- The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation.Haematologica · 2022Article
- Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients.Haematologica · 2022Article
- The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.Diagnostics (Basel, Switzerland) · 2021Review
- From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct.Cancers · 2021Review
- Article
- Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features.Frontiers in oncology · 2021Review
- Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype.Frontiers in oncology · 2021Review
- CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.Leukemia · 2020Article
- Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived.Current oncology reports · 2020Review
- Case Report: Chronic Lymphocytic Leukemia With a Rare Translocation t(14;19)(q32;q13) Involving IGHFrontiers in oncology · 2020Article
- European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms.Leukemia · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Anna PuiggrosLaboratori de Citogenètica Molecular, Laboratori de Citologia Hematològica, Servei de Patologia i Servei Hematologia, Hospital del Mar, Barcelona, Spain.
Rosa ColladoServicio de Hematología, Consorcio Hospital General Universitario, Valencia, Spain.
Maria José CalasanzServicio de Citogenética, Departamento de Genética, Universidad de Navarra, Pamplona, Spain.
Margarita OrtegaLaboratorio de Citogenética y Servicio de Hematología, Hospital Vall d'Hebron, Barcelona, Spain.
Neus Ruiz-XivilléServei Laboratori Hematologia, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Contra la Leucèmia Josep Carreras (IJC), Universitat Autònoma de Barcelona, Badalona, Spain.
Alfredo Rivas-DelgadoSecció d'Hematopatologia, Hospital Clínic, Institut d'Investigacions Biomèdiques Augustí Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Elisa LuñoServicio de Hematología, Hospital Universitario Central de Asturias, Oviedo, Spain.
Teresa GonzálezFundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain.
Blanca NavarroServicio de Hematología y Oncología Médica, Hospital Clínico Universitario de Valencia, Valencia, Spain.
MaDolores García-MaloServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, IMIB-Arrixaca, Murcia, Spain.
Alberto ValienteServicios de Genética y Hematología, Complejo Hospitalario de Navarra, Pamplona, Spain.
José Ángel HernándezServicio de Hematología, Hospital Universitario Infanta Leonor, Madrid, Spain.
María Teresa ArdanazServicio de Hematología, Hospital Txagorritxu, Vitoria, Spain.
María Ángeles PiñanServicio de Hematología, Hospital de Cruces, Bilbao, Spain.
María Laura BlancoServei d'Hematologia Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain.
María Hernández-SánchezServicio de Hematología, Hospital Universitario de Salamanca, IBSAL, IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca, CSIC, Salamanca, Spain.
Ana Batlle-LópezServicio de Hematología, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Rocío SalgadoLaboratorio de Citogenética, Servicio de Hematología, Fundación Jiménez Díaz, Madrid, Spain.
Marta SalidoLaboratori de Citogenètica Molecular, Laboratori de Citologia Hematològica, Servei de Patologia i Servei Hematologia, Hospital del Mar, Barcelona, Spain.
Ana FerrerLaboratori de Citogenètica Molecular, Laboratori de Citologia Hematològica, Servei de Patologia i Servei Hematologia, Hospital del Mar, Barcelona, Spain.
Pau AbrisquetaLaboratorio de Citogenética y Servicio de Hematología, Hospital Vall d'Hebron, Barcelona, Spain.
Eva GimenoLaboratori de Citogenètica Molecular, Laboratori de Citologia Hematològica, Servei de Patologia i Servei Hematologia, Hospital del Mar, Barcelona, Spain.
Eugènia AbellaLaboratori de Citogenètica Molecular, Laboratori de Citologia Hematològica, Servei de Patologia i Servei Hematologia, Hospital del Mar, Barcelona, Spain.
Christelle FerráServei Laboratori Hematologia, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Contra la Leucèmia Josep Carreras (IJC), Universitat Autònoma de Barcelona, Badalona, Spain.
María José TerolServicio de Hematología y Oncología Médica, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Francisco OrtuñoServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, IMIB-Arrixaca, Murcia, Spain.
Dolors CostaSecció d'Hematopatologia, Hospital Clínic, Institut d'Investigacions Biomèdiques Augustí Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Carol MorenoServei d'Hematologia Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain.
Félix CarbonellServicio de Hematología, Consorcio Hospital General Universitario, Valencia, Spain.
Francesc BoschLaboratorio de Citogenética y Servicio de Hematología, Hospital Vall d'Hebron, Barcelona, Spain.
Julio DelgadoSecció d'Hematopatologia, Hospital Clínic, Institut d'Investigacions Biomèdiques Augustí Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Blanca EspinetLaboratori de Citogenètica Molecular, Laboratori de Citologia Hematològica, Servei de Patologia i Servei Hematologia, Hospital del Mar, Barcelona, Spain.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genomic complexity identified by chromosome banding analysis (CBA) predicts a worse clinical outcome in CLL patients treated either with standard or new treatments. Herein, we analyzed the clinical impact of complex karyotypes (CK) with or without high-risk FISH deletions (
Indexed as
ATM deletionCLLcomplex karyotypeTP53 deletion
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.